Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement on Cosentyx® for hidradenitis suppurativa (HS)
Following this important milestone, Cosentyx has been listed in Québec
MONTRÉAL, July 10, 2025 /CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce the successful conclusion of negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) on the public reimbursement of Cosentyx (secukinumab) for the treatment of adults with moderate to severe hidradenitis suppurativa (HS), a chronic, painful and often debilitating inflammatory skin condition.1
Following the completion of these negotiations, Cosentyx has been listed in Québec, making it the first province to provide public reimbursement for Cosentyx in HS. Novartis remains committed to ongoing collaboration with provincial public drug programs across Canada to enable timely access and reimbursement for eligible patients nationwide.
"Too often, people living with HS feel like their condition is invisible within the healthcare system," said Latoya Palmer, Founder of Hidradenitis and Me Support Group. "As someone living with HS, it gives me hope to see this step forward. It feels validating and shows people like me that there is a path toward better support for those who need it most."
"For people living with moderate to severe HS, the condition can have a profound impact on daily life - not only due to physical symptoms, but also the emotional toll it can take," said Dr. Susan Poelman, Canadian and U.S. Board-Certified Dermatologist. "The conclusion of pCPA negotiations for Cosentyx is a promising step that could help expand possibilities for patients who have historically had limited treatment options."
"Concluding pCPA negotiations for Cosentyx in HS is an important step toward improving access to a therapy grounded in strong science and real patient need," said Mark Vineis, Country President, Novartis Pharmaceuticals Canada Inc. "At Novartis, we are committed to continuing to work with stakeholders across the healthcare system to help ensure eligible patients with HS have timely public access to innovative treatment options."
About Cosentyx® (secukinumab)
Cosentyx is the first and only fully human biologic that directly inhibits interleukin-17A, an important cytokine involved in many inflammatory diseases.2,3 Cosentyx is a proven medicine and has been studied clinically for more than 14 years. The medicine is backed by robust evidence, including 5 years of clinical data in adults supporting long-term safety and efficacy across moderate to severe plaque psoriasis (PsO), Axial spondyloarthritis (axSpA) and juvenile idiopathic arthritis (JIA).4,5,6,7,8,9 These data strengthen the position of Cosentyx as a treatment across moderate to severe PsO (adult and pediatric), PsA, HS, axial spondyloarthritis (axSpA), and juvenile idiopathic arthritis (JIA), including enthesitis-related arthritis and juvenile PsA. More than 1 million patients have been treated with Cosentyx worldwide since its launch in 2015.
About Novartis
Novartis is a focused innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide. Reimagine medicine with us.
In Canada, Novartis Pharmaceuticals Canada Inc. employs approximately 600 people to serve the evolving needs of patients and the healthcare system and invests over $30 million in R&D yearly in the country. For more information visit www.novartis.ca.
FA-11466794E_________________________________1 https://dermatology.ca/public-patients/diseases-conditions/skin-conditions/hidradenitis-suppurativa/#:~:text=Hidradenitis%20suppurativa%20(HS)%20is%20a%20chronic%2C%20painful%20skin%20condition,inner%20thighs%20and%2For%20buttocks.2 Novartis Europharm Limited. Cosentyx® (secukinumab): Summary of Product Characteristics. Accessed on June 6, 2025. Available at: https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_en.pdf3 Girolomoni G, Mrowietz U and Paul C. Psoriasis: rationale for targeting interleukin-17. Br J Dermatol 2012; 167: 717-724. Accessed on June 6, 2025. Available at: https://pubmed.ncbi.nlm.nih.gov/22716185/.4 Baraliakos X, Braun J, Deodhar A, et al. Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study. RMD Open 2019; 5: e001005.5 Bissonnette R, Luger T, Thaçi D, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol 2018; 32: 1507-1514.6 Mease PJ, Kavanaugh A, Reimold A, et al. Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study. ACR Open Rheumatol 2020; 2: 18-25.7 Data on file. CAIN457F2310 (MEASURE 1 and 2): Pooled Safety Data. Novartis Pharmaceuticals Corp; July 23, 2018.8 Data on file. CAIN457F2312 (FUTURE 2): 5 year-interim report. Novartis Pharmaceuticals Corp; May 2019.9 McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015; 386: 1137-1146.
SOURCE Novartis Pharmaceuticals Canada Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/July2025/10/c0606.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Business News
8 hours ago
- Time Business News
Pharma & Research Laboratories in Canada
Canada is recognized as a world leader in pharmaceutical research, development, and innovation. Highly equipped Pharmaceutical Laboratories and a regulatory structure that favours growth give the country a leading edge in medical and biotech advances. If you are a pharmaceutical company, healthcare provider, or a biotech start-up, the potential for partnerships with a reputable Canadian lab is both broad and profound. Pharmaceutical laboratories play a crucial role in developing safe and effective drugs and treatments for patients. These laboratories are key to: Conducting clinical research and trials. Developing new drugs and formulations. Maintaining compliance with quality standards and regulations. Advancing vaccine and biotechnology research. There are numerous reasons the world owes Pharma Laboratories a great debt for the company's significant contributions to public health. They are the unsung heroes of modern medicine, from cancer research to vaccine development. Lab Canada has been expanding at an unprecedented pace in the last few years. With strong government support, significant investment in research and development, and a highly skilled workforce, Canadian labs are making notable strides in pharmaceutical science. Canada is listed as one of the world's leaders in clinical trials, biologics research, and biotech innovation. The Canada lab has some of the best good manufacturing practices (GMP-compliant) and technology in the industry, which is unmatched anywhere. Many of these labs are also ISO-certified, meaning they adhere to international quality standards and maintain a safe testing environment. Most Canadian Pharmaceutical Laboratories Offer services that cater to all aspects of the pharmaceutical development cycle. These include: Analytical Services: Analysis for chemicals, stability testing, and testing of raw materials. Analysis for chemicals, stability testing, and testing of raw materials. Formulation: Dosage formulation including tablets, capsules, AND injectables, etc. Dosage formulation including tablets, capsules, AND injectables, etc. Microbiology Testing: Testing for harmful microorganisms in products. Testing for harmful microorganisms in products. Regulatory Submission: Supply relevant information for regulatory filings. Supply relevant information for regulatory filings. Bioavailability & Bioequivalence Studies: Efficacy of the drug being compared with the standard. From small batch testing to vast pharmaceutical manufacturing, be assured that Canadian Analytical Laboratories is our trusted partner in innovation and dependability. When choosing a laboratory, reliability, compliance, and innovation are non-negotiable. Here are some reasons why getting a Canadian lab is a good business decision: Elite Level Standards: Canadian labs comply with Health Canada & FDA standards. Canadian labs comply with Health Canada & FDA standards. Cutting-edge Technology: These laboratories are equipped with the best-of-breed tools, from AI-powered analytics to robotics automation. These laboratories are equipped with the best-of-breed tools, from AI-powered analytics to robotics automation. Expertise & Talent: With highly educated chemists, biologists, and lab techs, quality is a given. With highly educated chemists, biologists, and lab techs, quality is a given. Nut Data Integrity: Security and accuracy should be maintained in all testing activities. Security and accuracy should be maintained in all testing activities. Teamwork: Easily collaborate with research and manufacturing teams worldwide. Pharma Labs also services more than drug manufacturers. These include: Biotechnology Companies Healthcare Providers Nutraceutical Brands Academic and Research Institutions Veterinary Medicine Providers From diagnostics to commercial production, Laboratories Canada delivers tailored services to different industries. Laboratory needs continue to evolve in response to global health threats. Canada is investing heavily in AI for diagnostics, personalized medicine, and green chemistry. The future of Pharma Laboratories in Canada is bright, sustainable, and innovative. In today's fast-paced world, having the right partner can make all the difference when developing innovative pharmaceutical products. Pharma Laboratories Canada upholds the highest standards of quality, innovation, and compliance among its partnered drug developers and industry professionals in the pharmaceutical, biotechnology, and healthcare sectors. Whether you're introducing a new drug or in the process of testing, having a Canadian laboratory means your project is in reliable hands. When it comes to Research and Development, Canada laboratory represents trust, effectiveness, and innovation. Q1. What are the services provided by Pharma Laboratories in Canada? A: They provide analytical testing, formulation development, microbiology testing, support for clinical trials, and regulatory consulting. Q2. Do Canadian laboratories meet the international standard? A: Yes, most Canadian labs comply with GMP, ISO certifications, and follow FDA and Health Canada regulations. Q3. How Do I Find the Best Canadian Lab for My Project? A: Look at lab accreditation, experience, technology, turnaround times, and customer reviews. Q4. Do foreign pharmaceutical companies support Canadian labs? A: Absolutely, Canadian labs frequently partner with overseas clients and provide comprehensive services, including logistics, documentation, and regulatory applications. Q5. These labs are only for drugs? A: No, they additionally cater to the biotechnology, nutraceuticals, academic research, and veterinary sectors. TIME BUSINESS NEWS
Yahoo
11 hours ago
- Yahoo
Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.
Key Points President Trump's tariffs could erode healthcare companies' profits, but some may perform well regardless. Eli Lilly and Novartis have taken steps to mitigate the potential impact. Both drugmakers are innovative, deliver strong financial results, and have excellent dividends. 10 stocks we like better than Eli Lilly › President Donald Trump's trade policies have caused tumult on Wall Street. The president has pushed for aggressive tariffs on imported goods in an attempt to bring manufacturing jobs back to the country. Although there were hopes that certain sectors would be spared -- including healthcare -- it turns out that won't be the case. Higher duties on imports could increase companies' costs, which would squeeze their margins and bottom lines, and meaningfully hurt their stock performance. However, even with this threat, there are still some healthcare companies worth investing in, including Eli Lilly (NYSE: LLY) and Novartis (NYSE: NVS). 1. Eli Lilly Eli Lilly has been expanding its U.S.-based manufacturing capacity for years, but it has recently accelerated this effort. The pharmaceutical leader has now invested, or committed to invest, $50 billion to build or update manufacturing sites in the country since 2020, about half of which it announced during the first quarter. According to management, once it completes its ongoing projects, it will be able to manufacture 100% of medicines aimed at U.S. patients within the country while also increasing its exports. In other words, the drugmaker will be mostly insulated from the impact of Trump's tariffs. And there are other reasons to invest in Eli Lilly. Here are three: First, the company has demonstrated remarkable innovation in its core areas of diabetes and obesity in recent years. Its newer launches, Mounjaro and Zepbound, are already generating billions and allowing it to grow its revenue and earnings at a good rate. In the first quarter, its top line rose 45% year over year to $12.7 billion. Net income was $2.8 billion, 23% higher than the year-ago period. Results like these should be the norm in the next five years at least. Second, the company has an extensive pipeline. Lilly recently reported positive phase 3 results for an oral GLP-1 candidate, orforglipron. This was an important win for the company since its current GLP-1 medicines are administered subcutaneously, so orforglipron could attract some patients who want a more convenient option. And there are many other exciting candidates, even beyond diabetes and obesity care. Third, the company is an excellent dividend stock, despite its unimpressive forward yield of 0.8%. It has increased its payout by 102.7% in the past five years. But whether you seek growth or income, Eli Lilly is a top stock to buy now and hold for a long time, despite the threat of tariffs. 2. Novartis Novartis is following a similar blueprint to mitigate the impact of tariffs. The company announced it would invest $23 billion in the next five years to improve its U.S.-based manufacturing footprint. Although its results may suffer somewhat from the impact of tariffs in the meantime, the company should eventually be able to handle them, assuming the tariffs continue. It's another excellent healthcare stock to consider in this environment, particularly given its strong financial results and promising prospects. In the first quarter, net sales increased by 12% to $13.2 billion year over year. Net income was $4.5 billion, 22% higher than the year-ago period. Some might point out that Novartis is losing U.S. patent exclusivity for its heart failure medicine Entresto this year. In the first quarter, it was still its top-selling drug, generating $2.3 billion in sales, 20% higher than the prior-year quarter. This will be a significant loss, but management has prepared for it. Newer medicines should eventually replace Entresto, including Fabhalta, which treats paroxysmal nocturnal hemoglobinuria (a rare blood disease), and cancer drugs Scemblix and Pluvicto. All of them first earned approval in the U.S. between 2021 and 2023. In the first quarter, Pluvicto, the best-selling of the trio, generated revenue of $371 million, a 20% year-over-year increase. Furthermore, Novartis' deep pipeline will lead to even more launches. The company currently has over 100 ongoing programs. Lastly, Novartis is also a strong income stock. The drugmaker has increased its dividend for 28 consecutive years and currently offers a forward yield of 3.3%, significantly higher than the S&P 500's average yield of 1.3%. It should deliver solid returns for patient investors, despite an upcoming major patent cliff and potential impacts from tariffs. Should you invest $1,000 in Eli Lilly right now? Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 Prosper Junior Bakiny has positions in Eli Lilly. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm. was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Post
2 days ago
- New York Post
Psychiatrist reveals what marijuana does to the developing brain
The recreational use of marijuana has become more common in recent years. But some research has found that consuming cannabis could have negative effects on the body, especially the brain. A recent French study suggested that cannabis use raises the risk of heart attack and stroke more than cocaine, while a Canadian study found that dementia risk is connected to cannabis-related hospital visits in older individuals. In an interview with Fox News Digital, Dr. Daniel Amen — psychiatrist, brain imaging specialist and founder of Amen Clinics in California — confirmed that it's 'clear' people who use marijuana have lower blood flow in their brain, according to decades of brain imaging performed at his clinics. These findings — along with associations between marijuana and heart disease — have been supported by other recent research. 5 Research shows that consuming cannabis could have negative effects on the body, like the brain. alfa27 – 5 According to Dr. Daniel Amen, people who use marijuana have lower blood flow in their brain. Africa Studio – 'We've been lied to that marijuana is innocuous, that marijuana is good medicine,' Amen said. 'And I think for some people, it can be helpful. But teenagers who use it, or people in their 20s, have a higher incidence of anxiety, depression, suicide and psychosis.' In a new study that compared people who smoked cigarettes with those who smoked marijuana, the marijuana users sustained more lung damage, he mentioned. 'This is just not great for us,' Amen said. 5 'We've been lied to that marijuana is innocuous, that marijuana is good medicine,' Amen said. 'But teenagers who use it, or people in their 20s, have a higher incidence of anxiety, depression, suicide and psychosis.' amenic181 – 5 There are also associations between marijuana and heart disease. Victor Moussa – Amen noted one of the 'horrifying trends' he's seen is parents who smoke pot with their teens and young adults. 'It just makes me think we're going the wrong way,' he said. 5 Amen advises against parents smoking with their teens, as young adult brains are not fully developed, and engaging in cannabis can set them back mentally, causing issues like anxiety and depression. Impact Photography – While some people may argue that alcohol is worse for the body than marijuana, Amen stressed that 'neither of them are good for you.' 'Why would you want to consume something that makes your brain older than you are?' he asked. As the brain of a young adult is not fully developed, engaging in cannabis use can set back young people mentally, causing issues like anxiety and depression, Amen cautioned. 'When you start using marijuana, alcohol or other drugs, your development gets arrested,' he said. 'Many people don't really appreciate how important their brain is when they're 17, 18, 21 or 23, because it really doesn't finish developing until you're 25 or 26,' Amen said. 'And if you hurt it early, it might not ever catch up.'
